FHFrancis Jonathan Ha

Francis Jonathan Ha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francis Jonathan Ha has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of Lifestyle and Risk Factor Modification Clinics in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Yan Zhao, Francis J. Ha, Adam J. Brown, Nitesh Nerlekar

    BACKGROUND: Incidence and recurrence of atrial fibrillation (AF) are associated with several lifestyle risk factors. Lifestyle and risk factor modification (LRFM) clinics could have a role in comprehensively addressing AF from a holistic, patient-centered approach to improve clinical outcomes. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials evaluating the role of LRFM clinics compared with usual care in patients with AF. The primary end point was atrial arrhythmia recurrence. Secondary end points were AF and heart failure-related hospitalization, cardiovascular death, stroke or transient ischemic attack, and quality-of-life. RESULTS: Eleven randomized controlled trials with a total of 3364 patients were included (5 randomized controlled trials performed in the context of AF ablation). Mean age was 58 to 73 years, 30% were female, and 18% had persistent AF. Duration of follow-up ranged from 3 to 24 months. LRFM clinics significantly reduced the primary end point of arrhythmia recurrence compared with usual care after catheter ablation (odds ratio, 0.34 [95% CI, 0.23–0.51]; P 2 =0%). LRFM clinics also reduced AF-related hospitalization (odds ratio, 0.70 [95% CI, 0.51–0.98]; P =0.04, I 2 =21%) and improved quality-of-life (mean improvement on Short Form 36 Questionnaire, 8.90 [95% CI, 6.91–10.90]; P P =0.16), cardiovascular deaths ( P =0.79), or stroke/transient ischemic attack ( P =0.83). CONCLUSIONS: In this meta-analysis of randomized controlled trials, LRFM clinics reduced AF recurrence after ablation, reduced AF-related hospitalization, and improved quality of life. This study supports a comprehensive multidisciplinary lifestyle risk modification model of care to improve clinical outcomes in patients with AF.

  • Open Access

    Safety, Efficacy and Cost of Same-Day Discharge after Pulsed Field Ablation for Atrial Fibrillation: A Sub-study of the Multicentre SENTINEL Registry

    by Francis J Ha, James Sindone, Sohaib Virk, Austin Chin Chwan Ng, Chi Kin Law, Stephen Brienesse, Alexis Puvrez, David Ferreira, Bruno Scardamaglia Kistler, Julia Zhou, et al.

  • Open Access

    Obesity and Atrial Fibrillation: Weighing the Evidence

    by Francis J. Ha, Jit Yoei Tang, Shaun Khanna, Adam J. Brown, Emily Kotschet, Nitesh Nerlekar

    Obesity is a major, modifiable risk factor for atrial fibrillation (AF). Potential mechanisms include haemodynamic and metabolic changes, inflammation, changes in epicardial adipose tissue (EAT) composition and cardiovascular–kidney–metabolic (CKM) syndrome. EAT is increasingly recognised as a dynamic, pro-arrhythmic fat depot with a possible bidirectional relationship with AF, whereby AF itself may modulate EAT independent of weight change. CKM syndrome also underlies the complex interplay between obesity and AF. Despite guideline recommendations for at least 10% weight reduction in obese patients with AF, recent randomised trials focusing on weight reduction have largely failed to demonstrate clinically meaningful improvements in AF outcomes compared with catheter ablation or usual care. Incretin-based therapies including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a promising therapy offering sustained weight loss alongside broader cardiometabolic benefits, although randomised trials with AF as a primary endpoint are lacking. Comprehensive multidisciplinary lifestyle risk factor modification (LRFM) clinics that address cardiometabolic risk factors, AF education and medication adherence have shown benefit beyond weight reduction alone, although their delivery has been heterogeneous. This narrative review examines the evolving relationship between obesity and AF including a multidimensional cardiometabolic lens, EAT characterisation, contemporary randomised trials of weight reduction, and the emerging role of incretin-based therapies and LRFM clinics.

  • Open Access

    Pulsed Field Ablation for Atrial Fibrillation in Australia: A Large Tertiary Centre Analysis

    by Francis J. Ha, Duron Prinsloo, Edwin Xu, Hui Chen Han, David Adam, Stewart Healy, Mohammad Alasti, Colin Machado, Logan Bittinger, Sing Huey Cheng, et al.

  • Open Access

    Procedural Management of Atrial Fibrillation in Older Patients

    by Francis Jonathan Ha, Yan Zhao, Hui-Chen Han, Adam J Brown, Nitesh Nerlekar, Emily Kotschet

    Atrial fibrillation (AF) is becoming increasingly prevalent worldwide because of population aging and the widespread availability of continuous rhythm monitoring. While medical therapy remains central to management, several procedural strategies are being considered for older patients, including catheter ablation with pulsed field ablation (PFA), atrioventricular node ablation with conduction system pacing (CSP), leadless pacemaker (LPM) implantation, and percutaneous left atrial appendage occlusion (LAAO). Catheter ablation is an established therapy that reduces AF burden and improves quality of life; however, the role of catheter ablation in older patients has historically been limited by higher complication rates and greater arrhythmia recurrence. The emergence of PFA may expand the role of ablation because of its procedural efficiency and favorable safety profile, although randomized data in older patients remain limited. A pace-and-ablate strategy with CSP offers an alternative for older patients with symptomatic persistent AF or tachy-brady syndrome. Indeed, by engaging the native conduction system, CSP provides more physiological ventricular activation and may reduce the risk of pacing-induced cardiomyopathy. LPMs avoid the lead- and pocket-related complications associated with transvenous pacemakers and may be especially advantageous in frail older patients with multiple comorbidities. LAAO is a potential strategy for stroke prevention that is often proposed for patients unable to tolerate long-term anticoagulation, although randomized data remain conflicting. This narrative review evaluates the current evidence supporting these procedures in older patients with AF.

  • Open Access

    Representation and Clinical Outcomes of Asian Patients Undergoing Pulsed Field Ablation for Atrial Fibrillation in Australia: A Tertiary Centre Analysis

    by Francis J Ha, Edwin Xu, Nitesh Nerlekar, Adam J Brown, Emily Kotschet

    Background: Asian patients have been under-represented in AF ablation trials, with limited data available regarding pulsed field ablation (PFA). We compared procedural and clinical outcomes between Asian and white patients undergoing PFA for AF in a tertiary Australian centre in Australia. Methods: We performed a retrospective analysis of consecutive patients undergoing de novo PFA with a pentaspline catheter at the Australian centre between November 2022 and June 2025. Baseline demographic, procedural and follow-up data were collected. Outcomes, including procedural complications and arrhythmia recurrence, were compared between Asian and white patients. Arrhythmia recurrence was defined as documented AF, atrial flutter or atrial tachycardia lasting ≥30 seconds during follow-up. Results: Among 564 patients undergoing PFA, 38 (6.7%) were Asian and 504 (89%) were white. Asian patients had lower average BMI (26.8 versus 28.9 kg/m²; p=0.01) and were less likely to have persistent AF (21% vs 38%; p=0.038). There were no significant differences in procedural characteristics, including lesion set, procedure duration, left atrial dwell time or fluoroscopy time. No differences were observed in major or minor procedural complications between groups. At median follow-up of 7.6 months in Asian patients and 6.0 months in white patients, freedom from arrhythmia recurrence was similar (64.5% vs 70.5%; p=0.55). Rates of cardioversion, arrhythmia-related hospitalisation and repeat ablation were also comparable. Conclusion: Asian patients remain under-represented among patients undergoing PFA for AF in Australia despite comparable procedural safety and clinical efficacy outcomes to white patients. These findings highlight the need to address barriers to the use of healthcare services for AF in Asian populations.

  • Open Access

    Heterogeneity in endpoints, monitoring methods and blanking periods in clinical trials of atrial fibrillation ablation: a systematic review and meta-analysis

    by Francis J. Ha, Duron Prinsloo, Filip Pesevski, Hui Chen Han, Adam Brown, Nitesh Nerlekar, Emily Kotschet

    Background: Catheter ablation is a cornerstone of rhythm control in atrial fibrillation (AF). It is important that clinical trials in AF ablation have comparable endpoints and outcomes. We performed a systematic review of randomised controlled trials (RCTs) in AF ablation to evaluate endpoint definitions, monitoring methods, follow-up protocols and blanking periods. Methods: Electronic databases were searched for RCTs in catheter ablation for AF with ≥ 100 patients and ≥ 6 months of follow-up. Data were collected on study characteristics, patient demographics, arrhythmia monitoring methods, blanking periods, arrhythmia endpoints. Results: 129 RCTs ( n = 31,406) met inclusion criteria; 114 studies involved radiofrequency ablation and 43% patients had persistent AF. There were 19 different definitions of arrhythmia endpoints; the most common was AF/atrial tachyarrhythmia ≥ 30 s (102/129; 79%). Composite endpoints were used in 55 studies (43%). There were 11 different methods of monitoring arrhythmia recurrence; 24-h Holter (67/129; 52%) was most frequent, followed by transtelephonic/event-triggered monitoring (50/129; 39%), then 7-day Holter monitors (30/129; 23%). In the first year of follow-up, arrhythmia recurrence was most commonly assessed at 6 months (120/129; 93%), 12 months (117/129; 91%), and 3 months (116/129; 90%); 56 trials (43%) reported 1-month visit. Most trials used a 90-day blanking period (109/129, 84%). Recurrences during blanking period was reported in only 32 trials (25%). Conclusion: Significant heterogeneity exists in RCTs of AF ablation with varying definitions of arrhythmia recurrence, monitoring methods, follow-up schedules and blanking periods. Scientific consensus and more standardised assessment of arrhythmia recurrence is needed to improve comparability of clinical outcomes in RCTs of AF ablation.

  • Open Access

    Procedural characteristics and acute outcomes with different pulsed field ablation systems for atrial fibrillation

    by Francis J. Ha, Hui-Chen Han, Adam J. Brown, Nitesh Nerlekar, Emily Kotschet

    Background: Multiple different pulsed field ablation (PFA) systems have been developed for the treatment of atrial fibrillation (AF). An improved understanding of procedural workflow and outcomes are needed. Methods: We performed a comparative observational study of consecutive patients undergoing PFA with three systems at a tertiary centre: Farawave without electroanatomic mapping (Boston Scientific, US), Faraview with integrated electroanatomic mapping (Boston Scientific, US) and Varipulse (Johnson and Johnson MedTech, US). All patients underwent pulmonary vein isolation (PVI) with additional lesions at operator discretion. Results: A total of 150 patients undergoing PFA were included (50 with each system). Median age was 63–65 years ( p = 0.28) and 28–38% female ( p = 0.60). Persistent AF ranged from 40 to 62% ( p = 0.09). More patients received posterior wall (PW) ablation with Faraview (50%) compared with Varipulse (26%) and Farawave (24%) ( p = 0.01). Faraview was associated with more PV applications (52 versus 36; p < 0.001) although fewer PW applications (18 versus 24; p = 0.028) compared with Farawave. Procedure and left atrial catheter dwell times were higher with Varipulse compared with Farawave and Faraview ( p < 0.001), but fluoroscopy time was lower ( p < 0.001). Fluoroscopy use with Varipulse reduced in the second 25 cases compared with the first 25 cases ( p = 0.01). There was no difference in rate of major or minor adverse events between groups. Conclusions: These real-world data on different PFA systems highlight varying procedural workflows depending on catheter design and the availability of additional information such as electroanatomic mapping and tissue contact. Further randomised studies are needed to compare safety and efficacy of different PFA systems for AF.